|
1
|
Kamangar F, Dores GM and Anderson WF:
Patterns of cancer incidence, mortality, and prevalence across five
continents: defining priorities to reduce cancer disparities in
different geographic regions of the world. J Clin Oncol.
24:2137–2150. 2006. View Article : Google Scholar
|
|
2
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
|
3
|
Otsuji E, Yamaguchi T, Sawai K, et al:
Recent advances in surgical treatment have improved the survival of
patients with gastric carcinoma. Cancer. 82:1233–1237. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Horner MJ, Ries LAG, Krapcho M, et al:
SEER Cancer Statistics Review, 1975–2006. http://seer.cancer.gov/archive/csr/1975_2006/results_merged/sect_24_stomach.pdf.
Accessed April 12, 2009
|
|
5
|
Cunningham SC, Kamangar F, Kim MP, et al:
Survival after gastric adenocarcinoma serection: eighteen-year
experience at a single institution. J Gastrointest Surg. 9:718–725.
2005.PubMed/NCBI
|
|
6
|
Bang YJ, Van Cutsem E, Feyereislova A, et
al: Trastuzumab in combination with chemotherapy versus
chemotherapy alone for treatment of HER2-positive advanced gastric
or gastro-oesophageal junction cancer (ToGA): a phase 3,
open-label, randomized controlled trial. Lancet. 376:687–697. 2010.
View Article : Google Scholar
|
|
7
|
Cardoso F, Di Leo A, Larsimont D, et al:
Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock
proteins 27 and 70 in primary breast cancer and metastatic
ipsilateral axillary lymph nodes. Ann Oncol. 12:615–620. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Simon R, Nocito A, Huebscher T, et al:
Patterns of her-2/neu amplification and overexpression in primary
and metastatic breast cancer. J Natl Cancer Inst. 93:1141–1146.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chang HJ, Han SW, Oh DY, et al: Discordant
human epidermal growth factor receptor 2 and hormone receptor
status in primary and metastatic breast cancer and response to
trastuzumab. Jpn J Clin Oncol. 41:593–599. 2011. View Article : Google Scholar
|
|
10
|
Chan A, Morey A, Brown B, et al: A
retrospective study investigating the rate of HER2 discordance
between primary breast carcinoma and locoregional or metastatic
disease. BMC Cancer. 12:5552012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Marx AH, Tharun L, Muth J, et al: HER-2
amplification is highly homogenous in gastric cancer. Hum Pathol.
40:769–777. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fassan M, Ludwig K, Pizzi M, et al: Human
epithelial growth factor receptor 2 (HER2) status in primary and
metastatic esophagogastric junction adenocarcinomas. Hum Pathol.
43:1206–1212. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tafe LJ, Janjigian YY, Zaidinski M, et al:
Human epidermal growth factor receptor 2 testing in
gastroesophageal cancer: correlation between immunohistochemistry
and fluorescence in situ hybridization. Arch Pathol Lab Med.
135:1460–1465. 2011. View Article : Google Scholar
|
|
14
|
Hofmann M, Stoss O, Shi D, et al:
Assessment of a HER2 scoring system for gastric cancer: results
from a validation study. Histopathology. 52:797–805. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kunz PL, Mojtahed A, Fisher GA, et al:
HER2 expression in gastric and gastroesophageal junction
adenocarcinoma in a US population: clinicopathologic analysis with
proposed approach to HER2 assessment. Appl Immunohistochem Mol
Morphol. 20:13–24. 2012. View Article : Google Scholar
|
|
16
|
Kataoka Y, Okabe H, Yoshizawa A, et al:
HER2 expression and its clinicopathological features in resectable
gastric cancer. Gastric Cancer. 16:84–93. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim MA, Lee HJ, Yang HK, et al:
Heterogeneous amplification of ERBB2 in primary lesions is
responsible for the discordant ERBB2 status of primary and
metastatic lesions in gastric carcinoma. Histopathology.
59:822–831. 2011. View Article : Google Scholar
|
|
18
|
Lee S, de Boer WB, Fermoyle S, et al:
Human epidermal growth factor 2 testing in gastric carcinoma:
issues related to heterogeneity in biopsies and resections.
Histopathology. 59:832–840. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Takehara T, Kunitomo K, Kono K, et al:
Status of c-erbB-2 in gastric adenocarcinoma: a comparative study
of immunohistochemistry, fluorescence in situ hybridization and
enzyme-linked immuno-sorbent assay. Int J Cancer. 98:833–837. 2002.
View Article : Google Scholar
|
|
20
|
Yano T, Doi T, Ohtsu A, et al: Comparison
of HER2 gene amplification assessed by fluorescence in
situ hybridization and HER2 protein expression assessed by
immunohistochemistry in gastric cancer. Oncol Rep. 15:65–71.
2006.
|
|
21
|
Wolff AC, Hammond ME, Schwartz JN, et al;
American Society of Clinical Oncology; College of American
Pathologists. American Society of Clinical Oncology/College of
American Pathologists guideline recommendations for human epidermal
growth factor receptor 2 testing in breast cancer. J Clin Oncol.
25:118–145. 2007. View Article : Google Scholar
|
|
22
|
Bozzetti C, Negri FV, Lagrasta CA, et al:
Comparison of HER2 status in primary and paired metastatic sites of
gastric carcinoma. Br J Cancer. 104:1372–1376. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nakamura R, Yamamoto N, Onai Y, et al:
Importance of confirming HER2 overexpression of recurrence lesion
in breast cancer patients. Breast Cancer. 20:336–341. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim KC, Koh YW, Chang HM, et al:
Evaluation of HER2 protein expression in gastric carcinomas:
comparative analysis of 1,414 cases of whole-tissue sections and
595 cases of tissue microarrays. Ann Surg Oncol. 18:2833–2840.
2011. View Article : Google Scholar
|
|
25
|
Fusco N, Rocco EG, Del Conte C, et al:
HER2 in gastric cancer: a digital image analysis in pre-neoplastic,
primary and metastatic lesions. Mod Pathol. 26:816–824. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kochi M, Fujii M, Masuda S, et al:
Differing deregulation of HER2 in primary gastric cancer and
synchronous related metastatic lymph nodes. Diagn Pathol.
8:1912013. View Article : Google Scholar : PubMed/NCBI
|
